ID   WWOX_HUMAN              Reviewed;         414 AA.
AC   Q9NZC7; A8K323; Q5MYT5; Q96KM3; Q96RF2; Q9BTT8; Q9NPC9; Q9NRF4;
AC   Q9NRF5; Q9NRF6; Q9NRK1; Q9NZC5;
DT   22-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   10-MAY-2017, entry version 158.
DE   RecName: Full=WW domain-containing oxidoreductase;
DE            EC=1.1.1.-;
DE   AltName: Full=Fragile site FRA16D oxidoreductase;
DE   AltName: Full=Short chain dehydrogenase/reductase family 41C member 1;
GN   Name=WWOX; Synonyms=FOR, SDR41C1, WOX1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [GENOMIC
RP   DNA] OF 1-35, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=10786676;
RA   Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A.,
RA   Aldaz C.M.;
RT   "WWOX, a novel WW domain-containing protein mapping to human
RT   chromosome 16q23.3-24.1, a region frequently affected in breast
RT   cancer.";
RL   Cancer Res. 60:2140-2145(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4), NUCLEOTIDE
RP   SEQUENCE [GENOMIC DNA] OF 173-414, AND CHROMOSOMAL REARRANGEMENT.
RX   PubMed=10861292; DOI=10.1093/hmg/9.11.1651;
RA   Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S.,
RA   Nancarrow J.K., Woollatt E., Kremmidiotis G., Gardner A., Venter D.,
RA   Baker E., Richards R.I.;
RT   "Common chromosomal fragile site FRA16D sequence: identification of
RT   the FOR gene spanning FRA16D and homozygous deletions and
RT   translocation breakpoints in cancer cells.";
RL   Hum. Mol. Genet. 9:1651-1663(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=11719429;
RA   Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J.,
RA   Bergsagel P.L., Kiguchi K., Brenner A.J., Aldaz C.M.;
RT   "WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.";
RL   Cancer Res. 61:8068-8073(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORMS 1; 3
RP   AND 7), VARIANTS LEU-98; SER-111; TRP-120; THR-179; PHE-272; ALA-282
RP   AND HIS-314, AND INVOLVEMENT IN CANCERS.
RX   PubMed=11572989; DOI=10.1073/pnas.191175898;
RA   Paige A.J.W., Taylor K.J., Taylor C., Hillier S.G., Farrington S.,
RA   Scott D., Porteous D.J., Smyth J.F., Gabra H., Watson J.E.V.;
RT   "WWOX: a candidate tumor suppressor gene involved in multiple tumor
RT   types.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:11417-11422(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-179.
RC   TISSUE=Colon adenocarcinoma;
RA   Chang N.-S.;
RT   "Cloning of human WOX8 (WWOX v8).";
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=14695174;
RA   Watanabe A., Hippo Y., Taniguchi H., Iwanari H., Yashiro M.,
RA   Hirakawa K., Kodama T., Aburatani H.;
RT   "An opposing view on WWOX protein function as a tumor suppressor.";
RL   Cancer Res. 63:8629-8633(2003).
RN   [10]
RP   INTERACTION WITH MAPK8 AND TP53, AND MUTAGENESIS OF LYS-28; ASP-29 AND
RP   TYR-33.
RX   PubMed=12514174; DOI=10.1074/jbc.M208373200;
RA   Chang N.-S., Doherty J., Ensign A.;
RT   "JNK1 physically interacts with WW domain-containing oxidoreductase
RT   (WOX1) and inhibits WOX1-mediated apoptosis.";
RL   J. Biol. Chem. 278:9195-9202(2003).
RN   [11]
RP   INVOLVEMENT IN CANCERS.
RX   PubMed=15266310; DOI=10.1038/sj.bjc.6602023;
RA   Park S.-W., Ludes-Meyers J., Zimonjic D.B., Durkin M.E., Popescu N.C.,
RA   Aldaz C.M.;
RT   "Frequent downregulation and loss of WWOX gene expression in human
RT   hepatocellular carcinoma.";
RL   Br. J. Cancer 91:753-759(2004).
RN   [12]
RP   FUNCTION, INTERACTION WITH TFAP2C AND TFAP2A, AND DOMAIN.
RX   PubMed=15548692; DOI=10.1158/0008-5472.CAN-04-2055;
RA   Aqeilan R.I., Palamarchuk A., Weigel R.J., Herrero J.J., Pekarsky Y.,
RA   Croce C.M.;
RT   "Physical and functional interactions between the Wwox tumor
RT   suppressor protein and the AP-2gamma transcription factor.";
RL   Cancer Res. 64:8256-8261(2004).
RN   [13]
RP   INVOLVEMENT IN CANCERS.
RX   PubMed=15073125; DOI=10.1158/1078-0432.CCR-03-0096;
RA   Kuroki T., Yendamuri S., Trapasso F., Matsuyama A., Aqeilan R.I.,
RA   Alder H., Rattan S., Cesari R., Nolli M.L., Williams N.N., Mori M.,
RA   Kanematsu T., Croce C.M.;
RT   "The tumor suppressor gene WWOX at FRA16D is involved in pancreatic
RT   carcinogenesis.";
RL   Clin. Cancer Res. 10:2459-2465(2004).
RN   [14]
RP   INVOLVEMENT IN CANCERS.
RX   PubMed=15131042; DOI=10.1158/1078-0432.CCR-03-0594;
RA   Aqeilan R.I., Kuroki T., Pekarsky Y., Albagha O., Trapasso F.,
RA   Baffa R., Huebner K., Edmonds P., Croce C.M.;
RT   "Loss of WWOX expression in gastric carcinoma.";
RL   Clin. Cancer Res. 10:3053-3058(2004).
RN   [15]
RP   INTERACTION WITH LITAF; WBP1; FAM189B AND SCOTIN, MUTAGENESIS OF
RP   44-TRP--PRO-47 AND 85-TYR--PRO-88, DOMAIN, AND SUBCELLULAR LOCATION.
RX   PubMed=15064722; DOI=10.1038/sj.onc.1207680;
RA   Ludes-Meyers J.H., Kil H., Bednarek A.K., Drake J., Bedford M.T.,
RA   Aldaz C.M.;
RT   "WWOX binds the specific proline-rich ligand PPXY: identification of
RT   candidate interacting proteins.";
RL   Oncogene 23:5049-5055(2004).
RN   [16]
RP   FUNCTION, INTERACTION WITH TP73, DOMAIN, MUTAGENESIS OF TYR-33 AND
RP   TYR-61, PHOSPHORYLATION AT TYR-33, AND SUBCELLULAR LOCATION.
RX   PubMed=15070730; DOI=10.1073/pnas.0400805101;
RA   Aqeilan R.I., Pekarsky Y., Herrero J.J., Palamarchuk A., Letofsky J.,
RA   Druck T., Trapasso F., Han S.-Y., Melino G., Huebner K., Croce C.M.;
RT   "Functional association between Wwox tumor suppressor protein and p73,
RT   a p53 homolog.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4401-4406(2004).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH ERBB4.
RX   PubMed=16061658; DOI=10.1158/0008-5472.CAN-05-1150;
RA   Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M.,
RA   Pekarsky Y., Sudol M., Croce C.M.;
RT   "WW domain-containing proteins, WWOX and YAP, compete for interaction
RT   with ErbB-4 and modulate its transcriptional function.";
RL   Cancer Res. 65:6764-6772(2005).
RN   [18]
RP   PHOSPHORYLATION AT TYR-287 BY TNK2, UBIQUITINATION, MUTAGENESIS OF
RP   TYR-287, AND INTERACTION WITH TNK2.
RX   PubMed=16288044; DOI=10.1158/0008-5472.CAN-05-1127;
RA   Mahajan N.P., Whang Y.E., Mohler J.L., Earp H.S.;
RT   "Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role
RT   of Ack1 in polyubiquitination of tumor suppressor Wwox.";
RL   Cancer Res. 65:10514-10523(2005).
RN   [19]
RP   FUNCTION, INTERACTION WITH MDM2 AND TP53, PHOSPHORYLATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16219768; DOI=10.1074/jbc.M505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-,
RT   staurosporine-, and p53-mediated cell death, and its tyrosine 33-
RT   phosphorylated form binds and stabilizes serine 46-phosphorylated
RT   p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [20]
RP   DISEASE.
RX   PubMed=16223882; DOI=10.1073/pnas.0505485102;
RA   Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R.I., Cimmino A.,
RA   Zanesi N., Yendamuri S., Han S.-Y., Amadori D., Huebner K.,
RA   Croce C.M.;
RT   "WWOX gene restoration prevents lung cancer growth in vitro and in
RT   vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15611-15616(2005).
RN   [21]
RP   FUNCTION, PHOSPHORYLATION AT TYR-33, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH HYAL2.
RX   PubMed=19366691; DOI=10.1074/jbc.M806688200;
RA   Hsu L.-J., Schultz L., Hong Q., Van Moer K., Heath J., Li M.-Y.,
RA   Lai F.-J., Lin S.-R., Lee M.-H., Lo C.-P., Lin Y.-S., Chen S.-T.,
RA   Chang N.-S.;
RT   "Transforming growth factor beta1 signaling via interaction with cell
RT   surface Hyal-2 and recruitment of WWOX/WOX1.";
RL   J. Biol. Chem. 284:16049-16059(2009).
RN   [22]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DVL1; DVL2 AND
RP   DVL3.
RX   PubMed=19465938; DOI=10.1038/onc.2009.120;
RA   Bouteille N., Driouch K., Hage P.E., Sin S., Formstecher E.,
RA   Camonis J., Lidereau R., Lallemand F.;
RT   "Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor
RT   suppressor protein.";
RL   Oncogene 28:2569-2580(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-12 AND SER-14, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [24]
RP   INTERACTION WITH TMEM207.
RX   PubMed=22226915; DOI=10.1093/carcin/bgs001;
RA   Takeuchi T., Adachi Y., Nagayama T.;
RT   "A WWOX-binding molecule, transmembrane protein 207, is related to the
RT   invasiveness of gastric signet-ring cell carcinoma.";
RL   Carcinogenesis 33:548-554(2012).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   INVOLVEMENT IN SCAR12.
RX   PubMed=24456803; DOI=10.1186/1750-1172-9-12;
RA   Abdel-Salam G., Thoenes M., Afifi H.H., Koerber F., Swan D.,
RA   Bolz H.J.;
RT   "The supposed tumor suppressor gene WWOX is mutated in an early lethal
RT   microcephaly syndrome with epilepsy, growth retardation and retinal
RT   degeneration.";
RL   Orphanet J. Rare Dis. 9:12-12(2014).
RN   [27]
RP   INVOLVEMENT IN EIEE28, AND VARIANT EIEE28 ARG-47.
RX   PubMed=25411445; DOI=10.1136/jmedgenet-2014-102748;
RA   Mignot C., Lambert L., Pasquier L., Bienvenu T., Delahaye-Duriez A.,
RA   Keren B., Lefranc J., Saunier A., Allou L., Roth V., Valduga M.,
RA   Moustaine A., Auvin S., Barrey C., Chantot-Bastaraud S., Lebrun N.,
RA   Moutard M.L., Nougues M.C., Vermersch A.I., Heron B., Pipiras E.,
RA   Heron D., Olivier-Faivre L., Gueant J.L., Jonveaux P., Philippe C.;
RT   "WWOX-related encephalopathies: delineation of the phenotypical
RT   spectrum and emerging genotype-phenotype correlation.";
RL   J. Med. Genet. 52:61-70(2015).
RN   [28]
RP   STRUCTURE BY NMR OF 51-101.
RA   Kowalski K., Merkel A.L., Colella A., Richards R.I., Booker G.W.;
RT   "Solution structure of the second WW domain of WWOX.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [29]
RP   VARIANT PRO-291, AND INVOLVEMENT IN ESCR.
RX   PubMed=11956080;
RA   Kuroki T., Trapasso F., Shiraishi T., Alder H., Mimori K., Mori M.,
RA   Croce C.M.;
RT   "Genetic alterations of the tumor suppressor gene WWOX in esophageal
RT   squamous cell carcinoma.";
RL   Cancer Res. 62:2258-2260(2002).
RN   [30]
RP   VARIANTS SCAR12 THR-47 AND ARG-372.
RX   PubMed=24369382; DOI=10.1093/brain/awt338;
RA   Mallaret M., Synofzik M., Lee J., Sagum C.A., Mahajnah M., Sharkia R.,
RA   Drouot N., Renaud M., Klein F.A., Anheim M., Tranchant C., Mignot C.,
RA   Mandel J.L., Bedford M., Bauer P., Salih M.A., Schuele R., Schoels L.,
RA   Aldaz C.M., Koenig M.;
RT   "The tumour suppressor gene WWOX is mutated in autosomal recessive
RT   cerebellar ataxia with epilepsy and mental retardation.";
RL   Brain 137:411-419(2014).
CC   -!- FUNCTION: Putative oxidoreductase. Acts as a tumor suppressor and
CC       plays a role in apoptosis. Required for normal bone development
CC       (By similarity). May function synergistically with p53/TP53 to
CC       control genotoxic stress-induced cell death. Plays a role in TGFB1
CC       signaling and TGFB1-mediated cell death. May also play a role in
CC       tumor necrosis factor (TNF)-mediated cell death. Inhibits Wnt
CC       signaling, probably by sequestering DVL2 in the cytoplasm.
CC       {ECO:0000250, ECO:0000269|PubMed:11719429,
CC       ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:15548692,
CC       ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16219768,
CC       ECO:0000269|PubMed:19366691, ECO:0000269|PubMed:19465938}.
CC   -!- SUBUNIT: Interacts with TP53, p73/TP73 and MAPK8. Interacts with
CC       MAPT/TAU, RUNX2 and HYAL2 (By similarity). Forms a ternary complex
CC       with TP53 and MDM2. Interacts with ERBB4, LITAF and WBP1.
CC       Interacts with DVL1, DVL2 and DVL3. May interact with FAM189B and
CC       SCOTIN. Interacts with TNK2. Interacts with TMEM207. {ECO:0000250,
CC       ECO:0000269|PubMed:12514174, ECO:0000269|PubMed:15064722,
CC       ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:15548692,
CC       ECO:0000269|PubMed:16061658, ECO:0000269|PubMed:16219768,
CC       ECO:0000269|PubMed:16288044, ECO:0000269|PubMed:19366691,
CC       ECO:0000269|PubMed:19465938, ECO:0000269|PubMed:22226915}.
CC   -!- INTERACTION:
CC       Q9NYG5-2:ANAPC11; NbExp=4; IntAct=EBI-12040603, EBI-12224467;
CC       Q67FY2:Bcl9l (xeno); NbExp=3; IntAct=EBI-4320739, EBI-5234367;
CC       Q5SWW7:C10orf55; NbExp=4; IntAct=EBI-12040603, EBI-12809220;
CC       Q15038:DAZAP2; NbExp=4; IntAct=EBI-12040603, EBI-724310;
CC       Q60838:Dvl2 (xeno); NbExp=2; IntAct=EBI-4320739, EBI-641940;
CC       Q61527:Erbb4 (xeno); NbExp=3; IntAct=EBI-4320739, EBI-4398741;
CC       P81408:FAM189B; NbExp=2; IntAct=EBI-4320739, EBI-6366314;
CC       Q96MT4:LINC01600; NbExp=4; IntAct=EBI-12040603, EBI-12804988;
CC       Q99732:LITAF; NbExp=5; IntAct=EBI-4320739, EBI-725647;
CC       Q8N114:SHISA5; NbExp=2; IntAct=EBI-4320739, EBI-2115556;
CC       Q96G27:WBP1; NbExp=3; IntAct=EBI-4320739, EBI-3867685;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14695174,
CC       ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:16219768,
CC       ECO:0000269|PubMed:19366691, ECO:0000269|PubMed:19465938}. Nucleus
CC       {ECO:0000269|PubMed:14695174, ECO:0000269|PubMed:15064722,
CC       ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:19366691}.
CC       Mitochondrion {ECO:0000269|PubMed:14695174}. Golgi apparatus
CC       {ECO:0000305}. Note=Partially localizes to the mitochondria
CC       (PubMed:14695174). Translocates to the nucleus upon genotoxic
CC       stress or TNF stimulation (By similarity). Translocates to the
CC       nucleus in response to TGFB1 (PubMed:19366691). Isoform 5 and
CC       isoform 6 may localize in the nucleus. {ECO:0000250,
CC       ECO:0000269|PubMed:14695174, ECO:0000269|PubMed:19366691}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=1; Synonyms=FOR II, FOR2, WWOXv1, WWOX v8;
CC         IsoId=Q9NZC7-1; Sequence=Displayed;
CC       Name=2; Synonyms=FOR I, FOR1, WOX2, WWOXv2;
CC         IsoId=Q9NZC7-2; Sequence=VSP_016367, VSP_016369;
CC       Name=3; Synonyms=FOR III, FOR3, WOX3;
CC         IsoId=Q9NZC7-3; Sequence=VSP_016364, VSP_016365;
CC         Note=Variant in position: 182:K->E (found in a primary
CC         colorectal tumor and tumor cells).;
CC       Name=4; Synonyms=FOR IV;
CC         IsoId=Q9NZC7-4; Sequence=VSP_016358, VSP_016359;
CC       Name=5; Synonyms=WWOXdelta6-8, WWOXv4;
CC         IsoId=Q9NZC7-5; Sequence=VSP_016363;
CC       Name=6; Synonyms=WWOXdelta5-8, WWOXv3;
CC         IsoId=Q9NZC7-6; Sequence=VSP_016360;
CC       Name=7;
CC         IsoId=Q9NZC7-7; Sequence=VSP_016362, VSP_016366;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Strongly expressed in
CC       testis, prostate, and ovary. Overexpressed in cancer cell lines.
CC       Isoform 5 and isoform 6 may only be expressed in tumor cell lines.
CC       {ECO:0000269|PubMed:10786676, ECO:0000269|PubMed:11719429}.
CC   -!- DOMAIN: The WW 1 domain mediates interaction with TP53, and
CC       probably TP73, TFAP2C, LITAF and WBP1.
CC       {ECO:0000269|PubMed:15064722, ECO:0000269|PubMed:15070730,
CC       ECO:0000269|PubMed:15548692}.
CC   -!- PTM: Phosphorylated upon genotoxic stress. Phosphorylation of Tyr-
CC       33 regulates interaction with TP53, TP73 and MAPK8. May also
CC       regulate proapoptotic activity. Phosphorylation by TNK2 is
CC       associated with polyubiquitination and degradation.
CC       {ECO:0000269|PubMed:15070730, ECO:0000269|PubMed:16288044,
CC       ECO:0000269|PubMed:19366691}.
CC   -!- PTM: Ubiquitinated when phosphorylated by TNK2, leading to its
CC       degradation. {ECO:0000269|PubMed:16288044}.
CC   -!- DISEASE: Note=Defects in WWOX may be involved in several cancer
CC       types. The gene spans the second most common chromosomal fragile
CC       site (FRA16D) which is frequently altered in cancers
CC       (PubMed:10861292). Alteration of the expression and expression of
CC       some isoforms is associated with cancers. However, it is still
CC       unclear if alteration of WWOX is directly implicated in
CC       cancerogenesis or if it corresponds to a secondary effect
CC       (PubMed:10861292, PubMed:11572989, PubMed:15266310,
CC       PubMed:15073125, PubMed:15131042). {ECO:0000269|PubMed:10861292,
CC       ECO:0000269|PubMed:11572989, ECO:0000269|PubMed:15073125,
CC       ECO:0000269|PubMed:15131042, ECO:0000269|PubMed:15266310}.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of
CC       the esophagus. The most common types are esophageal squamous cell
CC       carcinoma and adenocarcinoma. Cancer of the esophagus remains a
CC       devastating disease because it is usually not detected until it
CC       has progressed to an advanced incurable stage.
CC       {ECO:0000269|PubMed:11956080}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 12 (SCAR12)
CC       [MIM:614322]: Spinocerebellar ataxia is a clinically and
CC       genetically heterogeneous group of cerebellar disorders. Patients
CC       show progressive incoordination of gait and often poor
CC       coordination of hands, speech and eye movements, due to
CC       degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCAR12 is additionally characterized by
CC       onset of generalized seizures in infancy, and delayed psychomotor
CC       development with mental retardation. Some patients may also show
CC       spasticity. {ECO:0000269|PubMed:24369382,
CC       ECO:0000269|PubMed:24456803}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 28 (EIEE28)
CC       [MIM:616211]: A form of epileptic encephalopathy, a heterogeneous
CC       group of severe childhood onset epilepsies characterized by
CC       refractory seizures, neurodevelopmental impairment, and poor
CC       prognosis. Development is normal prior to seizure onset, after
CC       which cognitive and motor delays become apparent.
CC       {ECO:0000269|PubMed:25411445}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases
CC       (SDR) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAP94227.1; Type=Frameshift; Positions=362; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/WWOXID508ch16q23.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF211943; AAF27049.1; -; mRNA.
DR   EMBL; AF212843; AAF27050.1; -; Genomic_DNA.
DR   EMBL; AH009490; AAF78197.1; -; Genomic_DNA.
DR   EMBL; AF227526; AAF82053.1; -; mRNA.
DR   EMBL; AF227527; AAF82054.1; -; mRNA.
DR   EMBL; AF227528; AAF82055.1; -; mRNA.
DR   EMBL; AF227529; AAF82056.1; -; mRNA.
DR   EMBL; AF395123; AAK81727.1; -; mRNA.
DR   EMBL; AF395124; AAK81728.1; -; mRNA.
DR   EMBL; AF325432; AAL05449.1; -; Genomic_DNA.
DR   EMBL; AF325423; AAL05449.1; JOINED; Genomic_DNA.
DR   EMBL; AF325424; AAL05449.1; JOINED; Genomic_DNA.
DR   EMBL; AF325425; AAL05449.1; JOINED; Genomic_DNA.
DR   EMBL; AF325426; AAL05449.1; JOINED; Genomic_DNA.
DR   EMBL; AF325427; AAL05449.1; JOINED; Genomic_DNA.
DR   EMBL; AF325428; AAL05449.1; JOINED; Genomic_DNA.
DR   EMBL; AF325430; AAL05449.1; JOINED; Genomic_DNA.
DR   EMBL; AF325431; AAL05449.1; JOINED; Genomic_DNA.
DR   EMBL; AF325429; AAL05450.1; -; Genomic_DNA.
DR   EMBL; AF325423; AAL05450.1; JOINED; Genomic_DNA.
DR   EMBL; AF325424; AAL05450.1; JOINED; Genomic_DNA.
DR   EMBL; AF325425; AAL05450.1; JOINED; Genomic_DNA.
DR   EMBL; AF325426; AAL05450.1; JOINED; Genomic_DNA.
DR   EMBL; AF325427; AAL05450.1; JOINED; Genomic_DNA.
DR   EMBL; AF325432; AAL05451.1; -; Genomic_DNA.
DR   EMBL; AF325423; AAL05451.1; JOINED; Genomic_DNA.
DR   EMBL; AF325424; AAL05451.1; JOINED; Genomic_DNA.
DR   EMBL; AF325425; AAL05451.1; JOINED; Genomic_DNA.
DR   EMBL; AF325426; AAL05451.1; JOINED; Genomic_DNA.
DR   EMBL; AF325433; AAL05451.1; JOINED; Genomic_DNA.
DR   EMBL; AY256821; AAP94227.1; ALT_FRAME; mRNA.
DR   EMBL; AK290438; BAF83127.1; -; mRNA.
DR   EMBL; BT007445; AAP36113.1; -; mRNA.
DR   EMBL; BC003184; AAH03184.1; -; mRNA.
DR   CCDS; CCDS42196.1; -. [Q9NZC7-1]
DR   CCDS; CCDS42197.1; -. [Q9NZC7-3]
DR   RefSeq; NP_001278926.1; NM_001291997.1.
DR   RefSeq; NP_057457.1; NM_016373.3. [Q9NZC7-1]
DR   RefSeq; NP_570607.1; NM_130791.3. [Q9NZC7-3]
DR   UniGene; Hs.461453; -.
DR   PDB; 1WMV; NMR; -; A=51-101.
DR   PDBsum; 1WMV; -.
DR   ProteinModelPortal; Q9NZC7; -.
DR   SMR; Q9NZC7; -.
DR   BioGrid; 119707; 250.
DR   IntAct; Q9NZC7; 94.
DR   MINT; MINT-1175612; -.
DR   STRING; 9606.ENSP00000457230; -.
DR   iPTMnet; Q9NZC7; -.
DR   PhosphoSitePlus; Q9NZC7; -.
DR   BioMuta; WWOX; -.
DR   DMDM; 74725363; -.
DR   EPD; Q9NZC7; -.
DR   MaxQB; Q9NZC7; -.
DR   PaxDb; Q9NZC7; -.
DR   PeptideAtlas; Q9NZC7; -.
DR   PRIDE; Q9NZC7; -.
DR   DNASU; 51741; -.
DR   Ensembl; ENST00000355860; ENSP00000348119; ENSG00000186153. [Q9NZC7-3]
DR   Ensembl; ENST00000402655; ENSP00000384238; ENSG00000186153. [Q9NZC7-6]
DR   Ensembl; ENST00000406884; ENSP00000384495; ENSG00000186153. [Q9NZC7-5]
DR   Ensembl; ENST00000408984; ENSP00000386161; ENSG00000186153. [Q9NZC7-2]
DR   Ensembl; ENST00000566780; ENSP00000457230; ENSG00000186153. [Q9NZC7-1]
DR   Ensembl; ENST00000569818; ENSP00000454485; ENSG00000186153. [Q9NZC7-4]
DR   GeneID; 51741; -.
DR   KEGG; hsa:51741; -.
DR   UCSC; uc002ffi.3; human. [Q9NZC7-1]
DR   CTD; 51741; -.
DR   DisGeNET; 51741; -.
DR   GeneCards; WWOX; -.
DR   HGNC; HGNC:12799; WWOX.
DR   HPA; HPA050992; -.
DR   MalaCards; WWOX; -.
DR   MIM; 133239; phenotype.
DR   MIM; 605131; gene.
DR   MIM; 614322; phenotype.
DR   MIM; 616211; phenotype.
DR   neXtProt; NX_Q9NZC7; -.
DR   OpenTargets; ENSG00000186153; -.
DR   Orphanet; 251510; 46,XY partial gonadal dysgenesis.
DR   Orphanet; 284282; Autosomal recessive cerebellar ataxia-epilepsy-intellectual disability syndrome due to WWOX deficiency.
DR   PharmGKB; PA37398; -.
DR   eggNOG; ENOG410INSS; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00760000119068; -.
DR   HOVERGEN; HBG078800; -.
DR   InParanoid; Q9NZC7; -.
DR   KO; K19329; -.
DR   OMA; YSNIHRS; -.
DR   OrthoDB; EOG091G0EI5; -.
DR   PhylomeDB; Q9NZC7; -.
DR   TreeFam; TF105428; -.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-8866904; Negative regulation of activity of TFAP2 (AP-2) family transcription factors.
DR   Reactome; R-HSA-8866907; Activation of the TFAP2 (AP-2) family of transcription factors.
DR   SignaLink; Q9NZC7; -.
DR   SIGNOR; Q9NZC7; -.
DR   ChiTaRS; WWOX; human.
DR   EvolutionaryTrace; Q9NZC7; -.
DR   GeneWiki; WWOX; -.
DR   GenomeRNAi; 51741; -.
DR   PRO; PR:Q9NZC7; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000186153; -.
DR   ExpressionAtlas; Q9NZC7; baseline and differential.
DR   Genevisible; Q9NZC7; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0090575; C:RNA polymerase II transcription factor complex; ISS:BHF-UCL.
DR   GO; GO:0050662; F:coenzyme binding; TAS:UniProtKB.
DR   GO; GO:0048037; F:cofactor binding; TAS:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0016491; F:oxidoreductase activity; TAS:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; TAS:UniProtKB.
DR   GO; GO:0001105; F:RNA polymerase II transcription coactivator activity; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0055114; P:oxidation-reduction process; TAS:UniProtKB.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; ISS:BHF-UCL.
DR   GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0048705; P:skeletal system morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0008202; P:steroid metabolic process; TAS:UniProtKB.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   InterPro; IPR002347; SDR_fam.
DR   InterPro; IPR001202; WW_dom.
DR   Pfam; PF00106; adh_short; 1.
DR   Pfam; PF00397; WW; 2.
DR   PRINTS; PR00081; GDHRDH.
DR   SMART; SM00456; WW; 2.
DR   SUPFAM; SSF51045; SSF51045; 2.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS01159; WW_DOMAIN_1; 2.
DR   PROSITE; PS50020; WW_DOMAIN_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Complete proteome;
KW   Cytoplasm; Disease mutation; Epilepsy; Golgi apparatus; Mitochondrion;
KW   NADP; Neurodegeneration; Nucleus; Oxidoreductase; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Tumor suppressor;
KW   Ubl conjugation; Wnt signaling pathway.
FT   CHAIN         1    414       WW domain-containing oxidoreductase.
FT                                /FTId=PRO_0000054815.
FT   DOMAIN       16     49       WW 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN       57     90       WW 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   NP_BIND     131    137       NADP. {ECO:0000250}.
FT   REGION      125    414       Interaction with MAPT. {ECO:0000250}.
FT   REGION      209    273       Mediates targeting to the mitochondria.
FT                                {ECO:0000250}.
FT   MOTIF        50     55       Nuclear localization signal.
FT                                {ECO:0000250}.
FT   ACT_SITE    293    293       Proton acceptor. {ECO:0000250}.
FT   BINDING     260    260       Substrate. {ECO:0000250}.
FT   MOD_RES      12     12       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES      14     14       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES      33     33       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15070730,
FT                                ECO:0000269|PubMed:19366691}.
FT   MOD_RES     287    287       Phosphotyrosine; by TNK2.
FT                                {ECO:0000269|PubMed:16288044}.
FT   VAR_SEQ      36     36       N -> K (in isoform 4).
FT                                {ECO:0000303|PubMed:10861292}.
FT                                /FTId=VSP_016358.
FT   VAR_SEQ      37    414       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:10861292}.
FT                                /FTId=VSP_016359.
FT   VAR_SEQ     137    414       GFETAKSFALHGAHVILACRNMARASEAVSRILEEWHKAKV
FT                                EAMTLDLALLRSVQHFAEAFKAKNVPLHVLVCNAATFALPW
FT                                SLTKDGLETTFQVNHLGHFYLVQLLQDVLCRSAPARVIVVS
FT                                SESHRFTDINDSLGKLDFSRLSPTKNDYWAMLAYNRSKLCN
FT                                ILFSNELHRRLSPRGVTSNAVHPGNMMYSNIHRSWWVYTLL
FT                                FTLARPFTKSMQQGAATTVYCAAVPELEGLGGMYFNNCCRC
FT                                MPSPEAQSEETARTLWALSERLIQERLGSQSG -> ATGSC
FT                                HHRVLCCCPRTGGSGRDVLQQLLPLHALTRSSERRDGPDPV
FT                                GAQREADPRTAWQPVRLSGAQSGWAHTPALCVSPHASARAG
FT                                PLPNVPPTQIRKSKGNKSSHNRVKNLKYQWEAGNSWGKVSL
FT                                FWGWARHRSLCFLVVACLKVKTCLVCRFRISLEKHQQFSFF
FT                                YCYRIA (in isoform 6).
FT                                {ECO:0000303|PubMed:11719429}.
FT                                /FTId=VSP_016360.
FT   VAR_SEQ     138    213       FETAKSFALHGAHVILACRNMARASEAVSRILEEWHKAKVE
FT                                AMTLDLALLRSVQHFAEAFKAKNVPLHVLVCNAAT -> KA
FT                                SCHVGRTLKHTRVEELSLLPTAINRELPPPCTVLLSQNWRV
FT                                WEGCTSTTAAAACPHQKLRAKRRPGPCGRSARG (in
FT                                isoform 7). {ECO:0000305}.
FT                                /FTId=VSP_016362.
FT   VAR_SEQ     173    352       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:11719429,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_016363.
FT   VAR_SEQ     173    189       HKAKVEAMTLDLALLRS -> KTKYHPPPEKCRIKIFH
FT                                (in isoform 3).
FT                                {ECO:0000303|PubMed:10861292}.
FT                                /FTId=VSP_016364.
FT   VAR_SEQ     190    414       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10861292}.
FT                                /FTId=VSP_016365.
FT   VAR_SEQ     214    414       Missing (in isoform 7). {ECO:0000305}.
FT                                /FTId=VSP_016366.
FT   VAR_SEQ     353    363       QQGAATTVYCA -> VSDCLVEGGHF (in isoform
FT                                2). {ECO:0000303|PubMed:10861292}.
FT                                /FTId=VSP_016367.
FT   VAR_SEQ     364    414       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10861292}.
FT                                /FTId=VSP_016369.
FT   VARIANT      47     47       P -> R (in EIEE28; dbSNP:rs730880292).
FT                                {ECO:0000269|PubMed:25411445}.
FT                                /FTId=VAR_072351.
FT   VARIANT      47     47       P -> T (in SCAR12; dbSNP:rs587777128).
FT                                {ECO:0000269|PubMed:24369382}.
FT                                /FTId=VAR_070992.
FT   VARIANT      98     98       P -> L (in dbSNP:rs144601717).
FT                                {ECO:0000269|PubMed:11572989}.
FT                                /FTId=VAR_023916.
FT   VARIANT     111    111       T -> S (in a Burkitt lymphoma cell line;
FT                                dbSNP:rs114755364).
FT                                {ECO:0000269|PubMed:11572989}.
FT                                /FTId=VAR_023917.
FT   VARIANT     120    120       R -> W (in a primary colorectal tumor and
FT                                a histiocytic lymphoma cell line;
FT                                dbSNP:rs141361080).
FT                                {ECO:0000269|PubMed:11572989}.
FT                                /FTId=VAR_023918.
FT   VARIANT     179    179       A -> T (in dbSNP:rs12918952).
FT                                {ECO:0000269|PubMed:11572989,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_023919.
FT   VARIANT     216    216       L -> V (in dbSNP:rs7201683).
FT                                /FTId=VAR_052323.
FT   VARIANT     272    272       L -> F (in dbSNP:rs186745328).
FT                                {ECO:0000269|PubMed:11572989}.
FT                                /FTId=VAR_023920.
FT   VARIANT     282    282       P -> A (in dbSNP:rs3764340).
FT                                {ECO:0000269|PubMed:11572989}.
FT                                /FTId=VAR_023921.
FT   VARIANT     291    291       L -> P (found in a esophageal cancer
FT                                sample; somatic mutation;
FT                                dbSNP:rs119487098).
FT                                {ECO:0000269|PubMed:11956080}.
FT                                /FTId=VAR_023922.
FT   VARIANT     314    314       R -> H (in a cervical carcinoma cell
FT                                line; dbSNP:rs73572838).
FT                                {ECO:0000269|PubMed:11572989}.
FT                                /FTId=VAR_023923.
FT   VARIANT     372    372       G -> R (in SCAR12; dbSNP:rs587777127).
FT                                {ECO:0000269|PubMed:24369382}.
FT                                /FTId=VAR_070993.
FT   MUTAGEN      28     28       K->T: No effect on interaction with TP53.
FT                                Abolishes interaction with MAPK8; when
FT                                associated with V-29.
FT                                {ECO:0000269|PubMed:12514174}.
FT   MUTAGEN      29     29       D->V: No effect on interaction with TP53.
FT                                Abolishes interaction with MAPK8; when
FT                                associated with T-28.
FT                                {ECO:0000269|PubMed:12514174}.
FT   MUTAGEN      33     33       Y->F: Loss of phosphorylation.
FT                                {ECO:0000269|PubMed:12514174,
FT                                ECO:0000269|PubMed:15070730}.
FT   MUTAGEN      33     33       Y->R: Abolishes interaction with TP53,
FT                                TP73, MAPK8 and ERBB4. Partial loss of
FT                                interaction with TFAP2C. Loss of
FT                                phosphorylation. Loss of the proapoptotic
FT                                activity. {ECO:0000269|PubMed:12514174,
FT                                ECO:0000269|PubMed:15070730}.
FT   MUTAGEN      44     47       WEHP->FEHA: Abolishes interaction with
FT                                LITAF. {ECO:0000269|PubMed:15064722}.
FT   MUTAGEN      61     61       Y->R: No effect on interaction with TP73.
FT                                {ECO:0000269|PubMed:15070730}.
FT   MUTAGEN      85     88       YLDP->ALDA: No effect on interaction with
FT                                LITAF. {ECO:0000269|PubMed:15064722}.
FT   MUTAGEN     287    287       Y->A: Loss of phosphorylation by TNK2.
FT                                {ECO:0000269|PubMed:16288044}.
FT   STRAND       63     67       {ECO:0000244|PDB:1WMV}.
FT   STRAND       73     80       {ECO:0000244|PDB:1WMV}.
FT   STRAND       83     86       {ECO:0000244|PDB:1WMV}.
SQ   SEQUENCE   414 AA;  46677 MW;  E4D9A649E6CB05DF CRC64;
     MAALRYAGLD DTDSEDELPP GWEERTTKDG WVYYANHTEE KTQWEHPKTG KRKRVAGDLP
     YGWEQETDEN GQVFFVDHIN KRTTYLDPRL AFTVDDNPTK PTTRQRYDGS TTAMEILQGR
     DFTGKVVVVT GANSGIGFET AKSFALHGAH VILACRNMAR ASEAVSRILE EWHKAKVEAM
     TLDLALLRSV QHFAEAFKAK NVPLHVLVCN AATFALPWSL TKDGLETTFQ VNHLGHFYLV
     QLLQDVLCRS APARVIVVSS ESHRFTDIND SLGKLDFSRL SPTKNDYWAM LAYNRSKLCN
     ILFSNELHRR LSPRGVTSNA VHPGNMMYSN IHRSWWVYTL LFTLARPFTK SMQQGAATTV
     YCAAVPELEG LGGMYFNNCC RCMPSPEAQS EETARTLWAL SERLIQERLG SQSG
//
